Menu Search
Equities

Bruker Corp

BRKR:NSQ

Bruker Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)56.74
  • Today's Change0.52 / 0.92%
  • Shares traded416.08k
  • 1 Year change-12.77%
  • Beta1.1776
Data delayed at least 15 minutes, as of Nov 22 2024 15:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform4
Hold3
Sell2
Strong Sell0

Share price forecast in USD

The 12 analysts offering 12 month price targets for Bruker Corp have a median target of 75.00, with a high estimate of 85.00 and a low estimate of 54.00. The median estimate represents a 33.40% increase from the last price of 56.22.
High51.2%85.00
Med33.4%75.00
Low-3.9%54.00

Dividends in USD

In 2023, Bruker Corp reported a dividend of 0.20 USD, equaling last years dividend. The 4 analysts covering the company expect dividends of 0.19 USD for the upcoming fiscal year, a decrease of 3.50%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Nov 05, 2024, Bruker Corp reported 3rd quarter 2024 earnings of 0.600 per share. This result was in line with the consensus of the 12 analysts following the company and under-performed last year's 3rd quarter results by 18.92%.
The next earnings announcement is expected on Jan 06, 2025.
Average growth rate-3.04%
Bruker Corp reported annual 2023 earnings of 2.68 per share on Feb 13, 2024.
Average growth rate+16.88%
More ▼

Revenue history & estimates in USD

Bruker Corporation had 3rd quarter 2024 revenues of 864.40m. This bettered the 859.38m consensus of the 11 analysts covering the company. This was 26.13% above the prior year's 3rd quarter results.
Average growth rate+4.60%
Bruker Corporation had revenues for the full year 2023 of 2.96bn. This was 17.14% above the prior year's results.
Average growth rate+9.84%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.